Abstracts

HIV AND SYPHILIS IN THE DISTRICT OF COLUMBIA

HIV and syphilis co-infection comprised 39% of primary or secondary (early) syphilis cases in the District of Columbia (DC) in 2018. These stages of syphilis are associated with increased HIV transmissibility. People living with HIV (PLH) are also at risk for severe manifestations of syphilis. We sought to determine effectiveness of syphilis treatment by assessing…

LONG-ACTING COFORMULATED BIODEGRADABLE IMPLANT FOR HIV PREVENTION AND CONTRACEPTION

Women worldwide face multiple health risks such as unintended pregnancy and HIV. Multipurpose prevention technologies (MPTs) can simultaneously address the need for contraception and prevention of infectious disease with one product. Here, we are developing a long-acting (LA) biodegradable implant comprising a multi-drug formulation for HIV prevention and contraception. We selected two well-characterized progestins, levonorgestrel…

PREDICTORS OF PrEP ADHERENCE AND RETENTION IN US CISGENDER WOMEN AT RISK FOR HIV

HIV pre-exposure prophylaxis (PrEP) effectiveness depends on adherence, which requires retention in PrEP care. We examined factors associated with PrEP adherence and retention among at-risk cisgender women prescribed oral PrEP. Adherence Enhancement Guided by Individualized Texting and Drug Levels (AEGiS) was a 48-week single-arm open-label demonstration study of daily oral tenofovir disoproxil fumarate/emtricitabine in cisgender…

ACCEPTABILITY AND CHOICE FOR 3 PLACEBO PRODUCTS USED WITH RECEPTIVE ANAL SEX

End-user perspectives are vital to the design of new biomedical HIV prevention products. Behaviorally congruent alternatives to condoms and daily oral Pre-Exposure Prophylaxis (PrEP) remain crucial. MTN-035 evaluated the acceptability of and preference for three placebo, non-gel delivery vehicles (insert, enema, suppository) that could be used to deliver PrEP prior to receptive anal sex (RAS).…